These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 13184258)

  • 1. [Use of intramuscular administration of heparin in anticoagulant therapy].
    BROUSTET ; POUQUET ; BRICAUD
    J Med Bord; 1954 Apr; 131(4):371-5. PubMed ID: 13184258
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anticoagulant treatment with heparin].
    Langer B; Wolosker M; Albers MT
    Rev Paul Med; 1982; 99(1):31-2. PubMed ID: 7146741
    [No Abstract]   [Full Text] [Related]  

  • 3. [The coagulation parameters in high-dosage intravenous heparin therapy].
    Weidmann B
    Dtsch Med Wochenschr; 1994 Mar; 119(12):442. PubMed ID: 8143564
    [No Abstract]   [Full Text] [Related]  

  • 4. [A heparin preparation with prolonged effect, heparin prolongatum for intramuscular injection; preliminary report].
    DOLLERUP E; HEIGAARD JJ; HOLTEN C
    Ugeskr Laeger; 1955 Oct; 117(42):1379-81. PubMed ID: 13281957
    [No Abstract]   [Full Text] [Related]  

  • 5. [Monitoring heparin therapy].
    Wettendorff P
    Rev Med Brux; 1983 Jan; 4(1):27-31. PubMed ID: 6836204
    [No Abstract]   [Full Text] [Related]  

  • 6. Low-dose heparin therapy.
    Chamberlain SL
    Am J Nurs; 1980 Jun; 80(6):1115-7. PubMed ID: 6446861
    [No Abstract]   [Full Text] [Related]  

  • 7. Failure to influence the blood coagulation time by sublingual administration of heparin.
    KENNEDY AC; BROWN A
    Glasgow Med J; 1952 Mar; 33(3):89-91. PubMed ID: 14906847
    [No Abstract]   [Full Text] [Related]  

  • 8. [The effect of subcutaneous depot heparin on certain coagulation parameters (preliminary report)].
    Petö I; Blaskó G; Sas G
    Orv Hetil; 1981 Jan; 122(3):145-6. PubMed ID: 7220045
    [No Abstract]   [Full Text] [Related]  

  • 9. Long duration of anticoagulant activity and protective effects of acharan sulfate in vivo.
    Li DW; Lee IS; Sim JS; Toida T; Linhardt RJ; Kim YS
    Thromb Res; 2004; 113(1):67-73. PubMed ID: 15081567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A train difference in anticoagulant response to subcutaneous administration of heparin in mice.
    Sue TK; Jaques LB; Yelland J
    Thromb Res; 1978 Jan; 12(1):5-13. PubMed ID: 644560
    [No Abstract]   [Full Text] [Related]  

  • 11. [Heparin. Mode of action, indications, administration].
    Kierulf P
    Tidsskr Nor Laegeforen; 1971 Oct; 91(29):2105-8. PubMed ID: 5130881
    [No Abstract]   [Full Text] [Related]  

  • 12. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Concerning the article "Problem of heparin dosage" by G. Mombelli].
    Krahenbuhl B
    Schweiz Med Wochenschr; 1984 Aug; 114(31-32):1102-3. PubMed ID: 6494861
    [No Abstract]   [Full Text] [Related]  

  • 14. Commentary on: The relationship between heparin level and activated clotting time in the adult cardiac surgery population.
    Fitzgerald D
    Perfusion; 2009 Mar; 24(2):97. PubMed ID: 19654151
    [No Abstract]   [Full Text] [Related]  

  • 15. Kinetic model for intravenous heparin infusion.
    Bauwens S; Dukes GE
    Am J Hosp Pharm; 1980 Jan; 37(1):26, 31, 37 passim. PubMed ID: 7361772
    [No Abstract]   [Full Text] [Related]  

  • 16. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.
    Kim YS; Murkin JM; Adams SJ
    Heart Surg Forum; 2004; 7(6):E599-604. PubMed ID: 15769695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of lysozyme on the anticoagulant action of heparin].
    GARAGNANI A; FACCHINI G
    Arch Patol Clin Med; 1957; 34(1):41-6. PubMed ID: 13479259
    [No Abstract]   [Full Text] [Related]  

  • 18. [Intramuscular heparin treatment in medial collum fractures--a lesser frequency of caput necrosis].
    Ohman U; Backman L; Björkegren NA; Fahlström G
    Nord Med; 1971 Apr; 85(13):415. PubMed ID: 5554428
    [No Abstract]   [Full Text] [Related]  

  • 19. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative studies of the anticoagulant effect of heparin and salmine sulfate on rabbit blood].
    ARDOINO AL
    Sperimentale; 1956; 106(6):458-67. PubMed ID: 13433061
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.